PURPOSE: The outpatient follow-up phase of the apomorphine (APO) 303 study assessed the long-term efficacy and safety of intermittent subcutaneous apomorphine for 'off' episodes in patients with advanced Parkinson's disease. METHODS: We conducted a 6-month open-label outpatient extension of an in-office dose-escalation study. Patients received apomorphine at a dose considered optimal based on safety and efficacy assessments during the dose-titration phase. Outpatient evaluation visits were scheduled at 1 and 2 weeks, and 1, 4 and 6 months. Efficacy parameters included changes in Unified Parkinson's Disease Rating Scale (UPDRS) motor scores; safety assessments included blood pressure (BP) monitoring. RESULTS: Apomorphine significantly (p<0.05) reduced UPDRS motor scores at 20, 40 and 90 minutes post-dose versus pre-dose at all evaluation visits. Significant (p<0.1) reductions from pre-dose in seated and standing systolic BP and diastolic BP were noted at various timepoints post-dose at evaluation visits; however, the changes did not increase over the course of the outpatient phase. The incidence of symptomatic hypotension also did not increase with long-term apomorphine use. CONCLUSIONS: The efficacy and general tolerability of subcutaneous apomorphine throughout this open-label outpatient study suggest that it is suitable for the long-term acute treatment of 'off' episodes in patients with advanced Parkinson's disease.
PURPOSE: The outpatient follow-up phase of the apomorphine (APO) 303 study assessed the long-term efficacy and safety of intermittent subcutaneous apomorphine for 'off' episodes in patients with advanced Parkinson's disease. METHODS: We conducted a 6-month open-label outpatient extension of an in-office dose-escalation study. Patients received apomorphine at a dose considered optimal based on safety and efficacy assessments during the dose-titration phase. Outpatient evaluation visits were scheduled at 1 and 2 weeks, and 1, 4 and 6 months. Efficacy parameters included changes in Unified Parkinson's Disease Rating Scale (UPDRS) motor scores; safety assessments included blood pressure (BP) monitoring. RESULTS:Apomorphine significantly (p<0.05) reduced UPDRS motor scores at 20, 40 and 90 minutes post-dose versus pre-dose at all evaluation visits. Significant (p<0.1) reductions from pre-dose in seated and standing systolic BP and diastolic BP were noted at various timepoints post-dose at evaluation visits; however, the changes did not increase over the course of the outpatient phase. The incidence of symptomatic hypotension also did not increase with long-term apomorphine use. CONCLUSIONS: The efficacy and general tolerability of subcutaneous apomorphine throughout this open-label outpatient study suggest that it is suitable for the long-term acute treatment of 'off' episodes in patients with advanced Parkinson's disease.
Authors: Ronald F Pfeiffer; Ludwig Gutmann; Keith L Hull; Peter B Bottini; James H Sherry Journal: Parkinsonism Relat Disord Date: 2006-10-18 Impact factor: 4.891
Authors: C G Goetz; G T Stebbins; H M Shale; A E Lang; D A Chernik; T A Chmura; J E Ahlskog; E E Dorflinger Journal: Mov Disord Date: 1994-07 Impact factor: 10.338
Authors: Claudia Carrarini; Mirella Russo; Fedele Dono; Martina Di Pietro; Marianna G Rispoli; Vincenzo Di Stefano; Laura Ferri; Filomena Barbone; Michela Vitale; Astrid Thomas; Stefano Luca Sensi; Marco Onofrj; Laura Bonanni Journal: Biomolecules Date: 2019-08-20
Authors: Eva Thijssen; Jonas den Heijer; David Puibert; Laurence Moss; Mingzu Lei; David Hasegawa; Kyo Keum; Ken Mochel; Mohammed Ezzeldin Sharaf; Tom Alfredson; Wenxiang Zeng; Emilie van Brummelen; Tatjana Naranda; Geert Jan Groeneveld Journal: Mov Disord Date: 2022-01-20 Impact factor: 9.698